<SEC-DOCUMENT>0001140361-23-028246.txt : 20230605
<SEC-HEADER>0001140361-23-028246.hdr.sgml : 20230605
<ACCEPTANCE-DATETIME>20230605092021
ACCESSION NUMBER:		0001140361-23-028246
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230605
FILED AS OF DATE:		20230605
DATE AS OF CHANGE:		20230605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		23991393

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc20053950_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finacial Solutions inc.
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div>&#160;</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">For the Month of June 2023</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39992</div>
      <div>&#160;
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="font-weight: 400;"> <br>
      </div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Immunocore Holdings plc</div>
      <div style="text-align: center; font-weight: bold;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">92 Park Drive</div>
      <div style="text-align: center; font-weight: bold;">Milton Park</div>
      <div style="text-align: center; font-weight: bold;">Abingdon, Oxfordshire OX14 4RY</div>
      <div style="text-align: center; font-weight: bold;">United Kingdom</div>
      <div style="text-align: center; font-weight: bold;">&#160;(Address of principal executive office)</div>
      <div>&#160;
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div>&#9746;&#160; Form 20-F&#160; &#160; &#9744;&#160; Form 40-F</div>
      <div>&#160;</div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">INCORPORATION BY REFERENCE</div>
      <div><br>
      </div>
      <div>
        <div style="text-align: justify; color: #000000;">This Report on Form 6-K (this &#8220;Report&#8221;) of Immunocore Holdings plc (the &#8220;Company&#8221;), excluding Exhibit 99.1 attached hereto, shall be deemed to be
          incorporated by reference into the Company&#8217;s registration statement on Form F-3ASR (File No. 333-264105) and the Company&#8217;s registration statements on Form S-8 (File Nos. 333-255182, 333-265000 and 333-271164) and to be a part thereof from the
          date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
        <div><br>
        </div>
        <div style="text-align: justify; color: #000000;">Exhibit 99.1 to this Report is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the
          &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Press Release</div>
      </div>
      <div>
        <div><font style="color: #000000;"> </font><br>
          </div>
      </div>
      <div>
        <div style="text-align: justify;"><font style="color: #000000;">On June 3, 2023, the Company issued a press release announcing its </font>presentation of two posters at the 2023 American Society for Clinical Oncology Meeting (&#8220;ASCO 2023&#8221;). <font style="color: rgb(0, 0, 0);">A copy of the press release is
              furnished as Exhibit 99.1 to this Report.</font></div>
        <div><br>
        </div>
        <div style="text-align: justify; color: #000000; font-style: italic;">Data Presented at the ASCO 2023 Conference</div>
        <div><br>
        </div>
      </div>
      <div style="text-align: justify;">The first poster is titled &#8220;<font style="font-style: italic;">Early ctDNA reduction may identify patients with stable disease
          and long OS on tebentafusp</font>&#8221; and included an analysis of circulating tumor DNA (&#8220;ctDNA&#8221;) data from the Phase 3 KIMMTRAK (tebentafusp-tebn) trial in HLA-A*02:01 patients with metastatic uveal melanoma (&#8220;mUM&#8221;). In this analysis, ctDNA
        reduction by week 9 was observed in 94% of patients (34/36) with detectable ctDNA at baseline, and this reduction was associated with longer overall survival (&#8220;OS&#8221;). These data were consistent with those presented at the 2023 American Association
        for Cancer Research Annual Meeting in showing that ctDNA reduction by week 9 was strongly associated with improved OS, even in patients with best RECIST response of progressive disease &#8211; further indicating that RECIST responses underestimate
        tebentafusp&#8217;s clinical benefits, and that early reduction in ctDNA may be a better predictor of long OS than radiographic response.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The second poster is titled &#8220;<font style="font-style: italic;">A Phase 2/3 trial in progress on tebentafusp as monotherapy
          and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced, non-uveal melanoma</font>&#8221; and described the Phase 2/3 trial that has started randomizing patients with previously treated advanced melanoma,
        excluding uveal melanoma, who have progressed on an anti-PD1, received prior ipilimumab and, if applicable, received a BRAF kinase inhibitor. Patients will be randomized to one of three arms including tebentafusp, as monotherapy or in combination
        with an anti-PD1, and a control arm.</div>
      <div style="text-align: justify;"> <br>
        </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Forward-Looking Statements</div>
      </div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify;"><font style="color: #000000;">This Report contains forward-looking statements within the meaning of the Private
            Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the therapeutic potential and expected clinical benefits of our product candidates, including overall survival benefit; expectations that
          </font>ctDNA reduction from tebentafusp is associated with overall survival benefit;<font style="color: rgb(0, 0, 0);"> expectations </font>indicating that RECIST responses
            underestimate tebentafusp&#8217;s clinical benefits and that ctDNA may be a better predictor of long OS than radiographic response;<font style="color: rgb(0, 0, 0);"> expectations regarding the development of
              the Company&#8217;s pipeline and the design, progress, timing, scope and results of the Company&#8217;s existing and planned clinical trials, including the Phase 3 KIMMTRAK (tebentafusp-tebn) trial in HLA-A*02:01 patients with mUM and the Phase 2/3 trial
              with tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced, non-uveal melanoma</font>. <font style="color: rgb(0, 0, 0);">The
              words "may," &#8220;might,&#8221; "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," &#8220;expect,&#8221; "estimate," &#8220;seek,&#8221; "predict," &#8220;future,&#8221; "project," "potential," "continue," "target" and similar words or expressions
              are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this Report are based on management's current expectations and beliefs and are
              subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Report, including, without
              limitation, risks associated with: the risk that the results of preclinical studies and early results from clinical trials may not be predictive of future clinical trial results; the impact of worsening macroeconomic conditions and the
              ongoing and evolving COVID-19 pandemic, the war in Ukraine or global geopolitical tension on the Company&#8217;s business, strategy, financial position and anticipated milestones, including the Company&#8217;s ability to conduct ongoing and planned
              clinical trials; the Company&#8217;s ability to obtain and maintain regulatory approval of its product candidates; the Company&#8217;s ability to obtain clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any
              future approved products, including as a result of supply chain disruptions; the Company&#8217;s ability and plans to launch, market and sell KIMMTRAK or any future approved products, and to continue to establish and expand a commercial
              infrastructure; the Company&#8217;s ability to successfully expand the approved indications for KIMMTRAK, or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials,
              whether due to the COVID-19 pandemic, patient enrollment delays or otherwise; unexpected safety or efficacy data observed during preclinical studies or clinical trials and the Company&#8217;s ability to successfully demonstrate the safety and
              efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; actions of regulatory agencies, which may affect the initiation, timing and
              progress of clinical trials or future regulatory approval; the Company&#8217;s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it is developing; the Company&#8217;s need for and ability to
              obtain additional funding on favorable terms or at all, including as a result of worsening macroeconomic conditions such as rising inflation and interest rates, bank failures, volatility in the capital markets and related market uncertainty,
              the COVID-19 pandemic, the war in Ukraine and global geopolitical tension; and the success of the Company&#8217;s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in
              greater detail in the section titled "Risk Factors" in the Company&#8217;s filings with the Securities and Exchange Commission, including the Company&#8217;s most recent Annual Report on Form 20-F, as supplemented by its most recent filings that the
              Company has made or may make with the SEC in the future. Any forward-looking statements represent the Company&#8217;s views only as of the date of this Report and should not be relied upon as representing its views as of any subsequent date. The
              Company does not assume any obligation to update any forward-looking statements, except as may be required by law.</font></div>
      </div>
      <div>
        <div><font style="color: #000000;"> </font><br>
          </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf78386d1b04546e1a1e9a6864a0bfff3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-weight: bold;">No.</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 90%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">
              <div style="color: rgb(0, 0, 255);"><a href="brhc20053950_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Press Release dated June 3, 2023.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
        duly authorized.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z425a776740f646aba1547c59af1741d1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 5.52%; vertical-align: top;">&#160;</td>
            <td style="width: 44.92%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div style="font-weight: bold;">IMMUNOCORE HOLDINGS <font style="color: rgb(0, 0, 0);">PLC</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.52%; vertical-align: middle;">&#160;</td>
            <td style="width: 44.92%; vertical-align: middle;">&#160;</td>
            <td style="width: 2.98%; vertical-align: bottom;">&#160;</td>
            <td style="vertical-align: bottom;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5.52%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Date:</div>
            </td>
            <td style="width: 44.92%; vertical-align: bottom; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">June 5, 2023</div>
            </td>
            <td style="width: 2.98%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>/s/ <font style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.52%; vertical-align: top;">&#160;</td>
            <td style="width: 44.92%; vertical-align: top;">&#160;</td>
            <td style="width: 2.98%; vertical-align: top;">&#160;</td>
            <td style="width: 4.99%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 41.51%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 5.52%; vertical-align: top;">&#160;</td>
            <td style="width: 44.92%; vertical-align: top;">&#160;</td>
            <td style="width: 2.98%; vertical-align: top;">&#160;</td>
            <td style="width: 4.99%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 41.51%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc20053950_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finacial Solutions inc.
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Exhibit 99.1</div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="text-align: right;"><img src="image00001.jpg"></div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO</div>
      <div style="color: rgb(0, 0, 0);"><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-style: italic;">Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer
        overall survival</div>
      <div><br>
      </div>
      <div style="text-align: justify;">(<font style="color: rgb(0, 0, 0);">OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md, 3 June 2023</font>) <u>Immunocore</u><font style="color: rgb(0, 0, 0);"><u> Holdings plc (Nasdaq: IMCR)</u></font>, a commercial-stage
        biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, is presenting today
        two posters at the 2023 American Society for Clinical Oncology meeting:</div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zf8194b1258324c659ec6c5d948c6d191" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 18pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify;">A poster including an analysis of circulating tumor DNA (ctDNA) data from the Phase 3 KIMMTRAK
                  (tebentafusp-tebn) trial in HLA-A*02:01 patients with metastatic uveal melanoma (mUM)</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z00ba9785bda440e2a81fff4b015190a4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; margin-left: 18pt;">&#8226;</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify;">A trial-in-progress poster describing the design of the Phase 2/3 trial with tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01
                  patients with previously treated advanced melanoma.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify;">&#8220;We have shown that KIMMTRAK can deliver significant OS benefit to patients with metastatic uveal melanoma, regardless of best RECIST response. We have now validated
        ctDNA reduction as an early surrogate for OS in two separate clinical trials,&#8221; said Koustubh Ranade, Vice President of Translational Medicine at Immunocore. &#8220;ctDNA reduction is one of the dual endpoints in our ongoing Phase 2/3 trial with
        tebentafusp in patients with previously treated advanced or metastatic melanoma.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In this analysis of the Phase 3 data for patients with best response of stable disease treated with KIMMTRAK, ctDNA reduction by week 9 was observed in 94% of patients
        (34/36) with detectable ctDNA at baseline, and this reduction was associated with longer overall survival (OS). These data were consistent with those presented at AACR 2023 in showing that ctDNA reduction by week 9 was strongly associated with
        improved OS, even in patients with best RECIST response of progressive disease &#8211; further indicating that RECIST responses underestimate tebentafusp&#8217;s clinical benefits, and that early reduction in ctDNA may be a better predictor of long OS than
        radiographic response.</div>
      <div><br>
      </div>
      <div>The Company also presented a trial-in-progress poster for the Phase 2/3 trial that has started randomizing patients with previously treated advanced melanoma, excluding
        uveal melanoma, who have progressed on an anti-PD1, received prior ipilimumab and, if applicable, received a BRAF kinase inhibitor. Patients will be randomized to one of three arms including tebentafusp, as monotherapy or in combination with an
        anti-PD1, and a control arm.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Poster details</div>
      <div><br>
      </div>
      <div><font style="font-weight: bold;">Title:</font> Early ctDNA reduction may identify patients
          with stable disease and long OS on tebentafusp</div>
      <div><font style="font-weight: bold;">Presenting author:</font> Dan Feng</div>
      <div><font style="font-weight: bold;">Session:</font> Melanoma/Skin cancers</div>
      <div><br>
        <div><font style="font-weight: bold;">Title:</font> A Phase 2/3 trial in progress on
            tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced, non-uveal melanoma</div>
        <div> <br>
          </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: right;">
        <div><img src="image00001.jpg"></div>
      </div>
      <div><font style="font-weight: bold;"> </font>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><font style="font-weight: bold;">Presenting author:</font> Diwakar Davar</div>
      <div><font style="font-weight: bold;">Session:</font> Melanoma/Skin cancers (Trial in Progress)</div>
      <div><br>
      </div>
      <div style="text-align: center;">##</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">About KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      <div>KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a
        lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore&#8217;s ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for
        the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">About Phase 3 IMCgp100-202 Trial</div>
      <div>IMCgp100-202 (NCT03070392) is a randomized pivotal trial that evaluated overall survival (OS) of KIMMTRAK compared to investigator&#8217;s choice (either pembrolizumab,
        ipilimumab, or dacarbazine) in HLA-A*02:01-positive adult patients with previously untreated mUM. KIMMTRAK demonstrated an unprecedented OS benefit with a Hazard Ratio (HR) in the intent-to-treat population favoring KIMMTRAK, HR=0.51 (95% CI: 0.37,
        0.71); p&lt; 0.0001, over investigator&#8217;s choice (82% pembrolizumab; 13% ipilimumab; 6% dacarbazine).</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">IMPORTANT SAFETY INFORMATION</div>
      <div><br>
      </div>
      <div><font style="font-weight: bold;">Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in
          patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.</font> Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea,
          vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients
          are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or
          discontinue KIMMTRAK depending on persistence and severity of CRS.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Skin Reactions</div>
      <div><br>
      </div>
      <div>Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions
        occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Elevated Liver Enzymes</div>
      <div><br>
      </div>
      <div>Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood
        bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-weight: bold;">
        <div style="text-align: right;"><img src="image00001.jpg"></div>
      </div>
      <div style="font-weight: bold;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="font-weight: bold;">Embryo-Fetal Toxicity</div>
      <div>KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during
        treatment with KIMMTRAK and 1 week after the last dose.</div>
      <div><br>
      </div>
      <div>The most common adverse reactions (&#8805;30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal
        pain, edema, hypotension, dry skin, headache, and vomiting. The most common (&#8805;50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased
        phosphate.</div>
      <div><br>
      </div>
      <div>For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">About Immunocore</div>
      <div style="text-align: justify; color: #000000;">Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211;
        Immune mobilizing monoclonal TCRs Against X disease &#8211; designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a
        deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore&#8217;s most advanced
        oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in the United States, European Union, Canada, Australia and the United Kingdom,
        having demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in mUM, a cancer that has historically proven to be insensitive to other immunotherapies.</div>
      <div>
        <div style="text-align: justify; color: #000000;">&#160;</div>
        <div style="text-align: justify; color: #000000; font-weight: bold;">Forward Looking Statements</div>
        <div style="text-align: justify; color: #000000;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the Private Securities Litigation Reform
          Act of 1995. Words such as &#8220;may,&#8221; &#8220;can,&#8221; &#8220;will,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking
          statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the therapeutic potential and expected
          clinical benefits of our product candidates, including overall survival benefit; expectations that ctDNA reduction from tebentafusp is strongly associated with overall survival benefit; expectations indicating that RECIST responses underestimate
          tebentafusp&#8217;s clinical benefits and that ctDNA may be a better predictor of longer OS than radiographic response; expectations regarding the development of Immunocore&#8217;s pipeline and the design, progress, timing, scope and results of Immunocore&#8217;s
          existing and planned clinical trials, including the timing of an OS update from the Phase 3 IMCgp100-202 trial and the trialPhase 2/3 trial with tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with
          previously treated advanced, non-uveal melanoma. Any forward-looking statements are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ
          materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond Immunocore&#8217;s control.</div>
        <div><br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: justify; color: #000000;">
          <div style="text-align: right;"><img src="image00001.jpg"></div>
        </div>
        <div style="text-align: justify; color: #000000;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
        <div style="text-align: justify; color: #000000;">These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions and the ongoing and evolving COVID-19
          pandemic on Immunocore&#8217;s business, strategy, clinical trials, financial position and anticipated milestones, including Immunocore&#8217;s ability to conduct ongoing and planned clinical trials; Immunocore&#8217;s ability to obtain a clinical supply of
          current or future product candidates, or commercial supply of KIMMTRAK or any future approved products, including as a result of supply chain disruptions, the COVID-19 pandemic, the war in Ukraine or global geopolitical tension; Immunocore&#8217;s
          ability to obtain and maintain regulatory approvals for its product candidates; Immunocore&#8217;s ability to develop, manufacture and commercialize its product candidates; Immunocore&#8217;s ability and plans in continuing to establish and expand a
          commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore&#8217;s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in
          additional geographies in the future; the delay of any current or planned clinical trials, whether due to the COVID-19 pandemic, patient enrollment delays or otherwise; Immunocore&#8217;s ability to successfully demonstrate the safety and efficacy of
          its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during pre-clinical studies or clinical trials; actions
          of regulatory agencies, which may affect the initiation, timing and progress of Immunocore&#8217;s clinical trials or future regulatory approval; Immunocore&#8217;s need for and ability to obtain additional funding, on favorable terms or at all, including as
          a result of worsening macroeconomic conditions such as rising inflation and interest rates, bank failures, volatility in the capital markets and related market uncertainty, the COVID-19 pandemic, the war in Ukraine and global geopolitical
          tension; Immunocore&#8217;s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it is developing; clinical trial site activation or enrollment rates that are lower than expected; and the
          success of Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the
          Securities and Exchange Commission, including Immunocore&#8217;s most recent Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 1, 2023, as well as discussions of potential risks,
          uncertainties, and other important factors in Immunocore&#8217;s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Immunocore undertakes no duty to update this
          information, except as required by law.</div>
        <div><br>
        </div>
      </div>
      <div>
        <div style="color: #535D60;"><font style="font-weight: bold; color: rgb(0, 0, 0);">CONTACT:</font><font style="color: rgb(0, 0, 0);">&#160;</font></div>
      </div>
      <div style="color: #000000; font-weight: bold;">Immunocore</div>
      <div style="color: #000000;">S&#233;bastien Desprez, Head of Communications</div>
      <div style="color: rgb(0, 0, 0);">T:&#160;+44 (0) 7458030732</div>
      <div style="color: rgb(0, 0, 0);">E: sebastien.desprez@immunocore.com</div>
      <div style="color: rgb(0, 0, 0);">Follow on Twitter and LinkedIn: @Immunocore</div>
      <div style="color: rgb(0, 0, 0);"><br>
      </div>
      <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Investor Relations &#160;</font><font style="color: rgb(0, 0, 0);"><br>
        Clayton Robertson, Head of Investor Relations</font></div>
      <div style="color: rgb(0, 0, 0);">T: +1 (215) 384-4781</div>
      <div style="color: rgb(0, 0, 0);">E: clayton.robertson@immunocore.com</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  H /L# 2(  A$! Q$!_\0
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M_BKJMW&(-#\#Z]-?R#"BXA,<:-_M''3\JZ_P#;>)8M'E?QE=6]Q?7$ID$,*
M+ A_@S_%_GDUFX2I^](U]I&I[L3%^ 5Q#/\ "K15@8$Q"2.0#^%O,8X/X$?G
M7H5>+S:#XE^&.NWE]X1L6UGPS>OYLVFJ?WL#=RGK^&??IFM&3XLZA-"L>F^!
MO$,M\X($<L!1%/;+8Z5<Z;G)RAJF13JJ$5">C14^-.;KX@?#VSM' OOMC2\=
M53*9/T.#^55OC!+J<'Q:\$2:#;076IK#<>3#.^U&/?)[<9K>^'_@[5Y/$D_C
M#QLT;:W,GEVUK&<I:1^GU_Q/<TGC;3;ZX^,O@>]M[.XEL[>.X$TZ1DI'D<;C
MT&:N,DI*.]DS.47*+D]+M&-XH\;?$SPYH\NI:EX:T=+6(@.\<S2[,]R V<5K
M?#OPQ=ZQK-OXY\2:M;ZG>S08LH[5<06Z$=L]3R1]<]37IEU;PW=M+;W,:RP2
MJ4=&&0RG@@UY/X+L=8^'GC2;P^MI>7OA._8S6=Q'&T@LW)Y5B.@_^L?6H4U*
M+459_H6X.,TY-M?DRG\<+>\N_B!X$@TR[%G>R2RK#<%-WEM\O..];/\ PB7Q
M%_Z'V/\ \ 5JC\9H]2M_&G@W5]/TB^U.+3Y)9)4M8BY_AP,@<5;_ .%J:I_T
M3_Q+_P!^3_A5KF<(\MOP[D/D527/?\>WD=?X*TK7]+M[E?$FMKJ\KN#$XA$?
MEC'(XZUTE<1X/\<7OB'5_L5SX5UC2H_+9_M%W'M3(Q\O3J<UV]<\TT_>.JFX
MN/NA1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
